<?xml version="1.0" encoding="UTF-8"?>
<ref id="B27-pharmaceutics-13-00387">
 <label>27.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Buckley</surname>
    <given-names>L.A.</given-names>
   </name>
   <name>
    <surname>Salunke</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Thompson</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Baer</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Fegley</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Turner</surname>
    <given-names>M.A.</given-names>
   </name>
  </person-group>
  <article-title>Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients</article-title>
  <source>Int. J. Pharm.</source>
  <year>2018</year>
  <volume>536</volume>
  <fpage>563</fpage>
  <lpage>569</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.07.042</pub-id>
  <pub-id pub-id-type="pmid">28729174</pub-id>
 </element-citation>
</ref>
